194 related articles for article (PubMed ID: 21130741)
1. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.
Ohno K; Amano Y; Kakuta H; Niimi T; Takakura S; Orita M; Miyata K; Sakashita H; Takeuchi M; Komuro I; Higaki J; Horiuchi M; Kim-Mitsuyama S; Mori Y; Morishita R; Yamagishi S
Biochem Biophys Res Commun; 2011 Jan; 404(1):434-7. PubMed ID: 21130741
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
Kakuta H; Sudoh K; Sasamata M; Yamagishi S
Int J Clin Pharmacol Res; 2005; 25(1):41-6. PubMed ID: 15864875
[TBL] [Abstract][Full Text] [Related]
3. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
Burnier M
J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
[TBL] [Abstract][Full Text] [Related]
5. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan for the reduction of cardiovascular morbidity and mortality.
Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan improves endothelial function in patients with essential hypertension.
Benndorf RA; Appel D; Maas R; Schwedhelm E; Wenzel UO; Böger RH
J Cardiovasc Pharmacol; 2007 Oct; 50(4):367-71. PubMed ID: 18049303
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan.
Bakheit AH; Abd-Elgalil AA; Mustafa B; Haque A; Wani TA
Profiles Drug Subst Excip Relat Methodol; 2015; 40():371-429. PubMed ID: 26051689
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2014 Dec; 27(12):1464-71. PubMed ID: 24871627
[TBL] [Abstract][Full Text] [Related]
14. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
Miura S; Saku K
Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
[TBL] [Abstract][Full Text] [Related]
15. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Liang B; Leenen FH
J Cardiovasc Pharmacol; 2008 May; 51(5):457-66. PubMed ID: 18418273
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
[TBL] [Abstract][Full Text] [Related]
17. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Harada N; Shimozawa N; Okajima K
Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
[TBL] [Abstract][Full Text] [Related]
18. Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.
Cicero AF; Veronesi M; Prandin MG; Di Gregori V; Ambrosioni E; Borghi C
Fundam Clin Pharmacol; 2009 Oct; 23(5):583-8. PubMed ID: 19555395
[TBL] [Abstract][Full Text] [Related]
19. Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.
Kishi T; Hirooka Y; Sunagawa K
Hypertens Res; 2012 Sep; 35(9):940-6. PubMed ID: 22573203
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
